The introduction of ruxolitinib, a JAK1/2 inhibitor, has provided an additional line of therapy, effective at controlling haematocrit, reducing spleen volume and reducing the symptom burden in polycythaemia vera (PV) and primary myelofibrosis (PMF) [9,10,11]. The gene discussed is JAK1; the disease is acquired polycythemia vera.